Buscar
BioMarin Pharmaceutical Inc
BMRNAñadir a la lista de seguimiento
56.580USD
-1.090-1.89%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
10.94BCap. mercado
40.56P/E TTM
Más Datos de BioMarin Pharmaceutical Inc Compañía
BioMarin Pharmaceutical Inc. is a global biotechnology company engaged in the development of genetic discovery into medicines that make an impact on the life of each patient. The Company has eight commercial therapies and a clinical and preclinical pipeline. Its commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno-associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Its key clinical programs include Vosoritide, BMN 333, BMN 390, BMN 351, BMN 349, and INZ-701. Its late-stage enzyme replacement therapy, INZ-701, is being developed for the treatment of ENPP1 deficiency.
Información de BioMarin Pharmaceutical Inc
Símbolo de cotizaciónBMRN
Nombre de la empresaBioMarin Pharmaceutical Inc
Fecha de salida a bolsaJul 23, 1999
Director ejecutivoHardy (Alexander)
Número de empleados3040
Tipo de seguridadOrdinary Share
Fin del año fiscalJul 23
Dirección770 Lindaro Street
CiudadSAN RAFAEL
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal94901
Teléfono14155066700
Sitio Webhttps://www.biomarin.com/
Símbolo de cotizaciónBMRN
Fecha de salida a bolsaJul 23, 1999
Director ejecutivoHardy (Alexander)
Ejecutivos de BioMarin Pharmaceutical Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Richard A. (Randy) Meier
Mr. Richard A. (Randy) Meier
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
127.36K
+5.90%
Mr. Alexander Hardy
Mr. Alexander Hardy
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
52.42K
-94.66%
Mr. Robert J. (Bob) Hombach, CPA
Mr. Robert J. (Bob) Hombach, CPA
Independent Director
Independent Director
42.71K
+17.54%
Dr. Maykin Ho, Ph.D.
Dr. Maykin Ho, Ph.D.
Independent Director
Independent Director
28.85K
+25.96%
Ms. Barbara W. Bodem
Ms. Barbara W. Bodem
Independent Director
Independent Director
14.39K
+52.03%
Dr. Athena M. Countouriotis, M.D.
Dr. Athena M. Countouriotis, M.D.
Independent Director
Independent Director
14.39K
+52.05%
Ms. Cristin Hubbard
Ms. Cristin Hubbard
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
3.71K
-62.46%
Dr. Gregory R Friberg, M.D.
Dr. Gregory R Friberg, M.D.
Executive Vice President, Chief Research & Development Officer
Executive Vice President, Chief Research & Development Officer
2.81K
-1848.04%
Mr. G. Eric Davis
Mr. G. Eric Davis
Executive Vice President, Secretary, Chief Legal Officer
Executive Vice President, Secretary, Chief Legal Officer
--
--
Mr. Brian R. Mueller, CPA
Mr. Brian R. Mueller, CPA
Chief Financial Officer, Executive Vice President, Principal Accounting Officer
Chief Financial Officer, Executive Vice President, Principal Accounting Officer
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Richard A. (Randy) Meier
Mr. Richard A. (Randy) Meier
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
127.36K
+5.90%
Mr. Alexander Hardy
Mr. Alexander Hardy
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
52.42K
-94.66%
Mr. Robert J. (Bob) Hombach, CPA
Mr. Robert J. (Bob) Hombach, CPA
Independent Director
Independent Director
42.71K
+17.54%
Dr. Maykin Ho, Ph.D.
Dr. Maykin Ho, Ph.D.
Independent Director
Independent Director
28.85K
+25.96%
Ms. Barbara W. Bodem
Ms. Barbara W. Bodem
Independent Director
Independent Director
14.39K
+52.03%
Dr. Athena M. Countouriotis, M.D.
Dr. Athena M. Countouriotis, M.D.
Independent Director
Independent Director
14.39K
+52.05%
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de BioMarin Pharmaceutical Inc?
Los cinco principales accionistas de BioMarin Pharmaceutical Inc son: Mr. Richard A. (Randy) Meier
¿Cuántas instituciones poseen acciones de BioMarin Pharmaceutical Inc (BMRN)?
A fecha de 2026Q1, 1355 instituciones poseen acciones de BioMarin Pharmaceutical Inc, con un valor de mercado combinado de aproximadamente 192.89M, lo que representa el 99.80% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -14513748.00.
¿Cuál es la mayor fuente de ganancias de BioMarin Pharmaceutical Inc?
El 2026Q1, el segmento empresarial Voxzogo generó la ganancia más alta para BioMarin Pharmaceutical Inc, ascendiendo a 926.92M y representando el 29.26% de la ganancia total.
